

John A Radford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388335/publications.pdf>

Version: 2024-02-01

272
papers

21,508
citations

8749

75
h-index

10441

139
g-index

275
all docs

275
docs citations

275
times ranked

16189
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
2	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.	0.8	830
3	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016, 374, 2419-2429.	13.9	629
4	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 1598-1607.	13.9	619
5	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
6	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013, 381, 1817-1826.	6.3	450
7	European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 317-317.	0.8	448
8	Phase III Trial of Consolidation Therapy With Yttrium-90-labeled Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	0.8	431
9	Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. <i>Journal of the National Cancer Institute</i> , 2007, 99, 206-214.	3.0	411
10	Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 576-584.	0.8	403
11	Imatinib mesylate (STI-571 Glivec®, Gleevec®,) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. <i>European Journal of Cancer</i> , 2003, 39, 2006-2011.	1.3	393
12	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	0.6	349
13	Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2001, 37, 870-877.	1.3	344
14	Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 1316-1323.	0.8	337
15	Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. <i>Lancet, The</i> , 2001, 357, 1172-1175.	6.3	332
16	How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. <i>British Journal of Pharmacology</i> , 2011, 163, 675-693.	2.7	306
17	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1433-1442.	5.1	306
18	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1824-1833.	3.3	298

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	0.6	255
20	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 ⁺ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4462-4469.	0.8	248
21	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	0.6	247
22	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3144-3150.	0.8	238
23	International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury. <i>Journal of Clinical Oncology</i> , 1999, 17, 423-423.	0.8	237
24	Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. <i>Journal of Pathology</i> , 2006, 209, 344-351.	2.1	230
25	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	1.3	216
26	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	5.1	211
27	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008, 19, 233-241.	0.6	203
28	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008, 112, 2248-2260.	0.6	199
29	Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. <i>Fertility and Sterility</i> , 2001, 75, 269-274.	0.5	194
30	Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. <i>Human Reproduction</i> , 2001, 16, 2056-2060.	0.4	193
31	⁹⁰ Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1977-1983.	0.8	192
32	The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.. <i>Journal of Clinical Oncology</i> , 1988, 6, 940-946.	0.8	178
33	Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4096-4104.	0.8	175
34	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 544-551.	0.8	172
35	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. <i>Annals of Oncology</i> , 2006, 17, 1749-1760.	0.6	171
36	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , 2018, 36, 2395-2404.	0.8	165

#	ARTICLE	IF	CITATIONS
37	Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 546-546.	0.8	163
38	Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2105-2112.	0.8	163
39	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab. <i>Blood</i> , 2005, 105, 4576-4582.	0.6	152
40	Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1647-1655.	0.8	152
41	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. <i>Journal of Pathology</i> , 2005, 205, 293-301.	2.1	149
42	Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency. <i>Journal of Clinical Oncology</i> , 1999, 17, 1493-1493.	0.8	143
43	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016, 127, 1531-1538.	0.6	143
44	Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2745-2752.	0.8	142
45	Phase I Evaluation of a Fully Human Anti- α 5 β 1 Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2128-2135.	3.2	136
46	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 r gBT /Overlock 10 Tf 9.1 135	0.8	135
47	Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2005, 23, 9208-9218.	0.8	130
48	Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.. <i>Journal of Clinical Oncology</i> , 1995, 13, 134-139.	0.8	128
49	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2000, 36, 61-67.	1.3	125
50	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012, 119, 3698-3704.	0.6	125
51	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	0.6	120
52	Fertility after treatment for cancer. <i>BMJ: British Medical Journal</i> , 1999, 319, 935-936.	2.4	118
53	<i>A20</i> deletion is associated with copy number gain at the <i>TNFA/B/C</i> locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. <i>Journal of Pathology</i> , 2009, 217, 420-430.	2.1	118
54	<i>A20</i> is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. <i>Leukemia</i> , 2010, 24, 483-487.	3.3	113

#	ARTICLE	IF	CITATIONS
55	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 2634-2645.	0.6	111
56	Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1469-1479.	0.8	109
57	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 773-779.	5.1	103
58	Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. <i>Clinical Endocrinology</i> , 2001, 55, 315-324.	1.2	102
59	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017, 52, 216-221.	1.3	102
60	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
61	Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. <i>BMJ: British Medical Journal</i> , 1997, 314, 343-343.	2.4	95
62	Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab. <i>Journal of Clinical Oncology</i> , 2005, 23, 7985-7993.	0.8	93
63	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , 2008, 19, 835-846.	0.6	93
64	Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 586-592.	0.8	92
65	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1530-1542.	5.1	91
66	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2015, 26, 1923-1929.	0.6	89
67	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , 2013, 98, 611-614.	1.7	88
68	Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. <i>British Journal of Cancer</i> , 2000, 82, 789-793.	2.9	86
69	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
70	Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a <sc>UK</sc> phase II study suggest activity and possible gender differences. <i>British Journal of Haematology</i> , 2012, 159, 154-163.	1.2	85
71	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. <i>Blood</i> , 2008, 111, 4764-4770.	0.6	84
72	Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. <i>Blood</i> , 2007, 109, 3922-3928.	0.6	83

#	ARTICLE	IF	CITATIONS
73	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
74	De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 282-287.	0.8	82
75	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	0.8	81
76	The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. <i>British Journal of Haematology</i> , 2002, 119, 408-411.	1.2	79
77	Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2010, 28, 3352-3359.	0.8	79
78	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	3.2	77
79	ChIVPP/EVA Hybrid Versus the Weekly VAPEC-B Regimen for Previously Untreated Hodgkin's Disease. <i>Journal of Clinical Oncology</i> , 2002, 20, 2988-2994.	0.8	76
80	Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. <i>British Journal of Cancer</i> , 2008, 98, 1403-1414.	2.9	76
81	Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. <i>British Journal of Cancer</i> , 2002, 87, 381-384.	2.9	75
82	Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 1989, 59, 276-282.	2.9	73
83	Phase II trial of zanolimumab (HuMax α CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 565-573.	1.2	73
84	Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1623-1631.	0.8	72
85	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	1.9	70
86	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	0.6	69
87	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
88	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. <i>Annals of Oncology</i> , 2017, 28, 2511-2516.	0.6	64
89	Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2010, 151, 346-353.	1.2	63
90	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. <i>Annals of Oncology</i> , 2011, 22, 739-745.	0.6	63

#	ARTICLE	IF	CITATIONS
91	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 465-469.	2.9	61
92	Current knowledge and future research directions in treatment-related second primary malignancies. <i>European Journal of Cancer, Supplement</i> , 2014, 12, 5-17.	2.2	59
93	Restoration of Fertility after Treatment for Cancer. <i>Hormone Research in Paediatrics</i> , 2003, 59, 21-23.	0.8	58
94	Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. <i>British Journal of Cancer</i> , 1998, 77, 1294-1299.	2.9	57
95	Chemotherapy for ovarian cancer - a consensus statement on standard practice. <i>British Journal of Cancer</i> , 1998, 78, 1404-1406.	2.9	57
96	Fractionated ⁹⁰ Y-ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218.	0.8	57
97	Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). <i>British Journal of Haematology</i> , 2014, 164, 834-840.	1.2	54
98	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
99	Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study. <i>Blood</i> , 2010, 116, 3955-3955.	0.6	52
100	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	2.2	50
101	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , 2013, 108, 2399-2406.	2.9	49
102	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 583-586.	1.2	49
103	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018, 103, 1351-1358.	1.7	49
104	Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. <i>European Journal of Cancer</i> , 1993, 29, 81-86.	1.3	48
105	Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1995, 13, 2379-2385.	0.8	48
106	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , 2011, 104, 719-725.	2.9	48
107	Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	48
108	An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. <i>Toxicological Sciences</i> , 2014, 140, 3-15.	1.4	47

#	ARTICLE	IF	CITATIONS
109	Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. <i>British Journal of Cancer</i> , 1990, 61, 749-754.	2.9	46
110	The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. <i>Clinical Endocrinology</i> , 2000, 52, 609-616.	1.2	46
111	The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. <i>British Journal of Cancer</i> , 2009, 101, 582-588.	2.9	46
112	A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1303-1309.	0.8	45
113	A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. <i>British Journal of Cancer</i> , 2001, 85, 29-35.	2.9	45
114	Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 1994, 69, 379-381.	2.9	43
115	Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. <i>BioTechniques</i> , 2009, 47, 587-596.	0.8	43
116	Assessment and Significance of Mediastinal Bulk in Hodgkin's Disease: Comparison Between Computed Tomography and Chest Radiography. <i>Journal of Clinical Oncology</i> , 1999, 17, 2493-2493.	0.8	42
117	Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. <i>JAAD Case Reports</i> , 2018, 4, 229-231.	0.4	41
118	Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. <i>British Journal of Cancer</i> , 1999, 80, 1405-1411.	2.9	40
119	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 334-342.	1.2	40
120	Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2601-2612.	0.8	38
121	A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2000, 11, 861-865.	0.6	38
122	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 570-578.	1.2	38
123	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCR1-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016, 175, 668-672.	1.2	38
124	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016, 101, e407-e410.	1.7	38
125	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1732-1741.	0.8	38
126	Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. <i>British Journal of Radiology</i> , 2006, 79, e40-e44.	1.0	37

#	ARTICLE	IF	CITATIONS
127	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). <i>Annals of Oncology</i> , 2006, 17, 1546-1552.	0.6	37
128	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 928-928.	0.6	36
129	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , 2016, 128, 1107-1107.	0.6	36
130	Ultrastructural Preservation of Ovarian Cortical Tissue Cryopreserved in Dimethylsulfoxide for Subsequent Transplantation into Young Female Cancer Patients. <i>Ultrastructural Pathology</i> , 2004, 28, 239-245.	0.4	33
131	YY1 expression predicts favourable outcome in follicular lymphoma. <i>Journal of Clinical Pathology</i> , 2011, 64, 125-129.	1.0	33
132	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2863-2869.	0.6	33
133	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 123-123.	0.6	33
134	Chemotherapy for Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma. <i>Drugs</i> , 1992, 44, 1-8.	4.9	30
135	Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study. <i>Annals of Oncology</i> , 2000, 11, 715-719.	0.6	30
136	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 359-369.	2.0	30
137	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 860-867.	1.2	30
138	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.. <i>Blood</i> , 2007, 110, 643-643.	0.6	29
139	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. <i>Blood</i> , 2022, 140, 851-860.	0.6	28
140	A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. <i>British Journal of Cancer</i> , 1993, 67, 1385-1390.	2.9	27
141	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 170, 886-890.	1.2	27
142	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , 2021, 192, 504-513.	1.2	27
143	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , 2019, 134, 767-767.	0.6	27
144	Mitomycin C and vinblastine in the treatment of advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1985, 21, 1475-1477.	0.9	26

#	ARTICLE	IF	CITATIONS
145	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.. <i>Journal of Clinical Oncology</i> , 1991, 9, 1446-1452.	0.8	26
146	Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. <i>British Journal of Cancer</i> , 1997, 75, 110-115.	2.9	24
147	International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. <i>Annals of Oncology</i> , 1999, 10, 13-20.	0.6	24
148	Achieving pregnancy against the odds: successful implantation of frozen-thawed embryos generated by ICSI using spermatozoa banked prior to chemo/radiotherapy for Hodgkin's disease and acute leukaemia: Case Report. <i>Human Reproduction</i> , 2001, 16, 107-109.	0.4	24
149	Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. <i>British Journal of Haematology</i> , 2005, 129, 322-332.	1.2	24
150	Microarray Gene Expression Analysis of Fixed Archival Tissue Permits Molecular Classification and Identification of Potential Therapeutic Targets in Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 223-232.	1.2	24
151	Older patients (aged ≥ 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	1.7	24
152	The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. <i>Annals of Oncology</i> , 2014, 25, 176-181.	0.6	23
153	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	2.5	22
154	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3591-3601.	0.8	21
155	A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIIB Hodgkin's disease: 10-year follow-up. <i>Annals of Oncology</i> , 1991, 2, 49-54.	0.6	20
156	Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: Results of treatment in 184 patients. <i>Annals of Oncology</i> , 1994, 5, 147-151.	0.6	20
157	Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. <i>British Journal of Haematology</i> , 2017, 179, 471-479.	1.2	20
158	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no involved field radiotherapy) after 3 Cycles ABVD. <i>Blood</i> , 2008, 112, 369-369.	0.6	20
159	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	0.6	20
160	2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 793-799.	0.6	19
161	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). <i>British Journal of Haematology</i> , 2021, 193, 63-71.	1.2	19
162	Precision medicine in diffuse large B-cell lymphoma: hitting the target. <i>Haematologica</i> , 2015, 100, 989-93.	1.7	19

#	ARTICLE	IF	CITATIONS
163	The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. <i>British Journal of Cancer</i> , 1990, 62, 127-132.	2.9	18
164	Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Journal of Cancer</i> , 1992, 28, 105-112.	1.3	18
165	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. <i>Annals of Oncology</i> , 1996, 7, 705-711.	0.6	18
166	An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. <i>British Journal of Cancer</i> , 1999, 80, 444-447.	2.9	18
167	Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 1999, 24, 271-277.	1.3	18
168	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 65-70.	2.0	18
169	PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome. <i>Journal of Clinical Pathology</i> , 2013, 66, 764-767.	1.0	17
170	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018, 182, 212-221.	1.2	17
171	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021, 5, 3387-3396.	2.5	17
172	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 144-146.	1.1	16
173	PET-Directed Therapy for Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 392-392.	13.9	16
174	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orchard Study (OMB110928). <i>Blood</i> , 2014, 124, 630-630.	0.6	16
175	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 203-206.	2.5	15
176	A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE). <i>Cancer</i> , 1994, 73, 470-475.	2.0	14
177	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. <i>Annals of Oncology</i> , 2006, 17, 1721-1722.	0.6	14
178	The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). <i>Leukemia and Lymphoma</i> , 2014, 55, 1796-1799.	0.6	14
179	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S154-S156.	1.2	13
180	Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1558-1561.	13.9	13

#	ARTICLE	IF	CITATIONS
181	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	0.6	13
182	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014, 124, 4453-4453.	0.6	13
183	Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10028-10028.	0.8	13
184	An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. <i>Annals of Oncology</i> , 1991, 2, 423-430.	0.6	12
185	Monocytoid B cell lymphoma.. <i>Journal of Clinical Pathology</i> , 1991, 44, 39-44.	1.0	12
186	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <i>Annals of Oncology</i> , 2010, 21, 568-573.	0.6	12
187	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5â€year results from a <sc>UK</sc> National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016, 173, 274-282.	1.2	12
188	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advancedâ€stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of highâ€risk patients from the ECHÉLONâ€1 study. <i>Hematological Oncology</i> , 2021, 39, 185-195.	0.8	12
189	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study. <i>Blood</i> , 2018, 132, 2874-2874.	0.6	12
190	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS7582-TPS7582.	0.8	12
191	Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: Results of a pilot study in 20 patients. <i>Annals of Oncology</i> , 1991, 2, 505-509.	0.6	11
192	Autotransplantation of ovarian tissue and the risk of disease transmission. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2004, 113, S48-S49.	0.5	11
193	Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2008, 99, 253-258.	2.9	11
194	QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 402-411.	1.2	11
195	Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. <i>PLoS ONE</i> , 2020, 15, e0231027.	1.1	11
196	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8506-8506.	0.8	11
197	Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7555-7555.	0.8	11
198	Prospective subgroup analyses of the randomized <sc>MCL</sc>â€02 (<sc>SPRINT</sc>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	1.2	10

#	ARTICLE	IF	CITATIONS
199	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
200	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 1618-1618.	0.6	10
201	Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 252-255.	1.1	9
202	Semen collection from young cancer patients. <i>Human Fertility</i> , 2001, 4, 131-134.	0.7	9
203	A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. <i>Journal of Pathology Informatics</i> , 2013, 4, 4.	0.8	9
204	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. <i>Blood</i> , 2010, 116, 594-594.	0.6	9
205	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016, 128, 1746-1746.	0.6	9
206	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	0.8	9
207	Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction. <i>BMJ: British Medical Journal</i> , 1983, 287, 727-727.	2.4	8
208	A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S139-S140.	1.2	8
209	Treatment for Early-Stage Hodgkin Lymphoma: Has Radiotherapy Had Its Day?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3783-3785.	0.8	8
210	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , 2013, 109, 2560-2565.	2.9	8
211	Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2017, 179, 841-843.	1.2	8
212	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	1.2	8
213	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 398-398.	0.6	8
214	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013, 122, 764-764.	0.6	8
215	The role of computed tomography in the management of ovarian tumours of borderline malignancy. <i>Clinical Radiology</i> , 1997, 52, 280-283.	0.5	7
216	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 757-757.	0.6	7

#	ARTICLE	IF	CITATIONS
217	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011, 118, 270-270.	0.6	7
218	Burkitt's Lymphoma of an Ileal Pouch Following Restorative Proctocolectomy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1596-E1597.	0.9	6
219	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020, 99, 105-112.	0.8	6
220	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7588-TPS7588.	0.8	6
221	Pseudoautosomal linkage of familial hodgkin's lymphoma: molecular analysis of a unique family with leri-weill dyschondrosteosis and hodgkins lymphoma. <i>British Journal of Haematology</i> , 2003, 121, 377-379.	1.2	5
222	A Randomized Study of Interferon β Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma. <i>Oncologist</i> , 2013, 18, 1189-1189.	1.9	5
223	Second Cancers after Treatment for Hodgkin's Lymphoma " Continuing Cause for Concern. <i>New England Journal of Medicine</i> , 2015, 373, 2572-2573.	13.9	5
224	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. <i>Ecancermedalscience</i> , 2016, 10, 608.	0.6	5
225	Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S278-S279.	0.2	5
226	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 173-174.	0.6	5
227	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	0.6	5
228	Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2008, 112, 2002-2002.	0.6	5
229	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8529-8529.	0.8	5
230	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , 2001, 358, 588.	6.3	4
231	Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 321-325.	0.9	4
232	Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 452-454.	1.3	4
233	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8613-TPS8613.	0.8	4
234	The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study. <i>Health Expectations</i> , 2022, 25, 116-124.	1.1	4

#	ARTICLE	IF	CITATIONS
235	Enlargement of a mediastinal mass during treatment for Hodgkin's Disease may be due to accumulation of fluid within thymic cysts. <i>Clinical Radiology</i> , 1995, 50, 61-62.	0.5	3
236	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),. <i>Blood</i> , 2011, 118, 3704-3704.	0.6	3
237	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015, 126, 2689-2689.	0.6	3
238	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 2980-2980.	0.6	3
239	Urinary-derived Monocyte-Colony Stimulating Factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). <i>Annals of Oncology</i> , 1993, 4, 877-881.	0.6	2
240	Limited field Radiotherapy for Early Stage, Infra-diaphragmatic Hodgkin's Lymphoma. <i>Clinical Oncology</i> , 2004, 16, 53-57.	0.6	2
241	Ovarian Tissue Banking. <i>Journal of Mammalian Ova Research</i> , 2007, 24, 8-13.	0.1	2
242	The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 402-402.	0.6	2
243	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. <i>Blood</i> , 2018, 132, 2956-2956.	0.6	2
244	Consolidation Radiotherapy Is Associated with Improved Outcomes after Chemotherapy for Advanced Hodgkin Lymphoma: Analysis of Results from the UKLG LY09 Trial (ISRCTN97144519). <i>Blood</i> , 2008, 112, 368-368.	0.6	2
245	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , 2011, 118, 2718-2718.	0.6	2
246	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015, 126, 517-517.	0.6	2
247	The management of Hodgkin's disease. <i>Annals of Oncology</i> , 1993, 4, 417-421.	0.6	1
248	A Doxorubicin-Based Regimen used in the Treatment of Elderly Patients with High-Grade Non-Hodgkin's Lymphoma. <i>Clinical Oncology</i> , 2000, 12, 153-157.	0.6	1
249	What about the impact on patient health?. <i>BMJ: British Medical Journal</i> , 2007, 335, 60.3-60.	2.4	1
250	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórkami B. Wyniki międzynarodowego, wielośrodkowego, badania II fazy z ibrutinibem (PCI-32765) - EHA.1 Encore. <i>Acta Haematologica Polonica</i> , 2013, 44, 314-318.		1
251	XVI. Early stage Hodgkin lymphoma. <i>Hematological Oncology</i> , 2015, 33, 84-86.	0.8	1
252	Treatment of Hodgkin lymphoma in older patients. <i>Blood</i> , 2015, 126, 2768-2769.	0.6	1

#	ARTICLE	IF	CITATIONS
253	The ranibizumab saga of drug profiteering. <i>BMJ: British Medical Journal</i> , 2008, 337, a1532-a1532.	2.4	1
254	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. <i>Blood</i> , 2006, 108, 2723-2723.	0.6	1
255	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	0.6	1
256	Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.. <i>Blood</i> , 2007, 110, 359-359.	0.6	1
257	Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET "negative"™ after 3 Cycles of ABVD Chemotherapy.. <i>Blood</i> , 2008, 112, 1449-1449.	0.6	1
258	A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4481-4481.	0.6	1
259	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. <i>Blood Advances</i> , 2022, 6, 4736-4739.	2.5	1
260	Growth Factors and the Microenvironment. , 1993, , 36-43.		0
261	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , 2001, 358, 588.	6.3	0
262	Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3309-3309.	0.8	0
263	PCN65 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA RECEIVING 90Y-IBRITUMOMABTIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY. <i>Value in Health</i> , 2008, 11, A74.	0.1	0
264	019â€¦Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk?. <i>Heart</i> , 2017, 103, A16-A17.	1.2	0
265	Letter comments on a published article in the <i>New England Journal of Medicine</i> . <i>European Journal of Cancer</i> , 2018, 104, 250-251.	1.3	0
266	Reply to H.J.A. Adams et al and C. Kobe et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 3325-3326.	0.8	0
267	YY1 Expression Predicts Survival in Follicular and Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2033-2033.	0.6	0
268	A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. <i>Blood</i> , 2008, 112, 4828-4828.	0.6	0
269	Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). <i>Blood</i> , 2013, 122, 1814-1814.	0.6	0
270	Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. <i>Blood</i> , 2015, 126, 1516-1516.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015, 126, 1499-1499.	0.6	0
272	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. <i>Blood</i> , 2016, 128, 2978-2978.	0.6	0